UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
PROXY STATEMENT PURSUANT TO SECTION 14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934
Filed by the Registrant x
Filed by a Party other than the Registrant o
Check the appropriate box:
o | Preliminary Proxy Statement | ||||||||||
o | Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | ||||||||||
o | Definitive Proxy Statement | ||||||||||
x | Definitive Additional Materials | ||||||||||
o | Soliciting Materials Pursuant to ยง240.14a-12 | ||||||||||
Halozyme Therapeutics, Inc. | |||||||||||
(Name of Registrant as Specified in Its Charter) | |||||||||||
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) | |||||||||||
Payment of Filing Fee (Check the appropriate box): | |||||||||||
x | No fee required | ||||||||||
o | Fee paid previously with preliminary materials | ||||||||||
o | Fee computed on table in exhibit required by item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
![proxyaddcard1.jpg](https://capedge.com/proxy/DEFA14A/0001159036-24-000025/proxyaddcard1.jpg)
![proxyaddcard2.jpg](https://capedge.com/proxy/DEFA14A/0001159036-24-000025/proxyaddcard2.jpg)